explore -WSS

explore

author：Wikipedia 2025-09-27 12:55:12 - browse：4737

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

WSS

Boston's new lab space is opening empty

WuXi out of biotech trade group, U.S. and China relations to blame

How many hemophilia patients actually want gene therapy?

Elizabeth Holmes on track for early release from her 11

How many hemophilia patients actually want gene therapy?

Readout Newsletter: Bristol, Sangamo, Gilead, and more

hotspot

explore

hotspot

Apple is now the first public company to be valued at $3 trillion

Beach reads and more: STAT's 2023 summer book list

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First U.S. drug developed to treat liver disease MASH is approved

Cancer drug shortages should be causing more outrage

Readout Newsletter: Bristol, Sangamo, Gilead, and more

The cancer drug shortage isn’t new — and neither are the solutions

Petition to FDA: Get the lead out of consumer hair dyes

Malaria cases in Florida and Texas: Here’s what you need to know

What to know about OceanGate, the company behind the missing Titanic submersible

entertainment

Pushing for an NIH office for post

Medicare coverage of Wegovy, once blocked, now looks possible

HHS secretary Becerra pressed on Change HealthCare cyberattack

What to know about OceanGate, the company behind the missing Titanic submersible

Boston's new lab space is opening empty

UCLA team creates talking throat patch for voice disorders

Wikipedia

Wikipedia

knowledge

knowledge